Biomedical subjects

Y Segawa

Publications and source records attributed to Y Segawa.

166 records · Page 10Linked to original sources

PubMedDate not supplied

Clinical investigation of bronchioloalveolar carcinoma: a retrospective analysis of 53 patients in a single institution.

BACKGROUND: Bronchioloalveolar carcinoma (BAC) has been reported to have unique clinicopathological features. PATIENTS AND METHODS: This retrospective study was performed using data base including 871 patients treated for primary lung cancer between 1981 and 1995. RESULTS: The patients with BAC included a larger proportion of female (P = 0.029) and smoked less (P = 0.002) than those with non-BAC. There was no difference in survival between surgically resected patients with BAC and those with non-BAC. Clinical Stage IV patients with BAC had a better response to chemotherapy than did those with non-BAC. Survival in the former group was better than that in the latter on univariate analysis, but the significance of this difference was not confirmed multivariate analysis. CONCLUSION: The patients with BAC included a larger proportion of females and smoked less than those with non-BAC. Treatment results for BAC was comparable to those for non-BAC.

Adenocarcinoma, Bronchiolo-Alveolar↗

PubMedDate not supplied

Evaluation of the relationship between serum carcinoembryonic antigen level and treatment outcome in surgically resected clinical-stage I patients with non-small-cell lung cancer.

The relationship between preoperative serum carcinoembryonic antigen (CEA) level and treatment outcome for 39 clinical-stage I patients with surgically resected non-small-cell lung cancer (NSCLC) was retrospectively studied. Serum CEA levels were measured with an enzyme-linked immunosorbent assay kit, with the upper limit of normal defined as 6.7 ng/mL based on the 95% specificity level for benign lung disease in our hospital. Patients with serum CEA > or = 6.7 ng/mL (n = 9) were more likely to have advanced disease at surgery than those with serum CEA < 6.7 ng/mL (n = 30) (77.8% vs 16.7%, p = 0.0049). This increase in disease stage at surgery was mainly due to mediastinal lymph node metastasis. The sensitivity and specificity of serum CEA in the detection of pathological N2 disease were 62.5% and 87.1%, respectively. Survival for the high CEA group was significantly worse than that for the low CEA group (median survival time, 40.2 vs 75.8 months, p = 0.0125). Relapse-free survival for the high CEA group was also poorer than that of the low CEA group (p = 0.0032). In a multivariate analysis, serum CEA level was the most dominant factor affecting relapse-free survival (hazard ratio = 6.68, p = 0.0053). These findings suggest that preoperative serum CEA level is useful not only in detection of mediastinal lymph node metastasis, but also in prediction of survival for clinical-stage I patients with NSCLC.

Adenocarcinoma↗

PubMedDate not supplied

Cisplatin-resistant human small cell lung cancer cell line shows collateral sensitivity to vinca alkaloids.

A cisplatin-resistant cell line, SBC-3/CDDP, was established from a human small-cell lung cancer cell line, SBC-3. The SBC-3/CDDP cells were 13.1-fold more resistant to cisplatin than the parent SBC-3 cells. We investigated the cellular changes of this cell line with regard to the development of resistance to cisplatin. The SBC-3/CDDP cells showed various characteristics as follows: a) increased intracellular glutathione and glutathione S-transferase content b) decreased intracellular accumulation of cisplatin, c) increased topoisomerase I activity and the same topoisomerase II activity as the parent SBC-3 cells, and 4) strong cross-resistance to the platinum analogues and mitomycin C, moderate cross-resistance to 7-ethyl-10-hydroxy-camptothecin (SN-38), 4-hydroperoxy cyclophosphamide, etoposide, Adriamycin and methotrexate, and collateral sensitivity to vinca alkaloids and 5-fluorouracil. From these observations, the SBC-3/CDDP cells could be useful as a well characterized cisplatin-resistant cell line, and the resistance pattem in this cell line will give us much information for eradication of cisplatin-resistant tumor cells.

ATP Binding Cassette Transporter, Subfamily B, Mem↗

PubMedDate not supplied

Elevated vascular endothelial growth factor levels in sera of patients with lung cancer.

BACKGROUND: Vascular endothelial growth factor (VEGF) overexpression has been observed in several malignant tumors, and VEGF level in serum appears to be correlated with tumor burden in cancer patients. PATIENTS AND METHODS: Serum VEGF levels were measured in 70 patients with lung cancer including 23 with adenocarcinoma, 19 with squamous cell carcinoma, 3 with large cell carcinoma, and 25 with small cell carcinoma, and in 30 patients with benign lung disease and 13 healthy subjects with an enzyme immunoassay. RESULTS: VEGF levels (mean +/- SD; pg/ml) were 834 +/- 699 and 732 +/- 529 in patients with lung cancer and benign lung disease, respectively, and were significantly higher than those in healthy subjects (264 +/- 129) (P < 0.01). There were no differences between VEGF levels categorized by histology, disease stage, or distant metastasis for lung cancer patients. CONCLUSIONS: Although serum VEGF levels were increased in lung cancer patients, this increase might not have been related to tumor burden.

Adult↗